Ipamorelin vs GHRP-2: Growth Hormone Releasing Peptides Compared
Both compounds stimulate growth hormone, but their human and animal studies answer different questions. Compare what was measured before drawing conclusions about muscle gain, appetite or long-term treatment.
At-a-Glance Comparison
| Question | Ipamorelin | GHRP-2 |
|---|---|---|
| Identity | Synthetic pentapeptide GH secretagogue | Synthetic GH secretagogue, also called pralmorelin |
| Human hormone research | Healthy-male infusion PK/PD study; eight men at each of five exposure levels | IV hormone-response and diagnostic research; responses depend on conditions |
| Selectivity | Favorable ACTH/cortisol findings in animals; not matched long-term human safety proof | Acute human ACTH and prolactin responses documented |
| GH units | A modeled production rate is not an injected dose or a universal serum peak | No matched comparison establishes universal IU-per-pulse peaks |
| Appetite | No long-term appetite advantage established by the studies compared here | Seven-man acute SC-infusion study increased test-meal intake |
| Clinical endpoint | Postoperative trial had neutral key and secondary efficacy comparisons | Acute hormone and food-intake results do not establish muscle gain |
| Dosing and timing | Study-specific infusions do not validate routine repeated self-injections | Study-specific testing/infusion does not validate a bodybuilding cycle |
| Long-term safety | Not established by short IV research or animal selectivity | No general safety ranking or protective cycle established |
| Combinations | No validated ipamorelin/GHRP-2 side-effect-offsetting regimen in these sources | No evidence here that adding ipamorelin prevents adverse hormone effects |
| Cost | Compare a dated quote for the exact product and services | Compare equivalent supply, prescribing and monitoring rather than vial price alone |
Ipamorelin: Where the Selectivity Finding Comes From
The original pharmacology experiments used rat pituitary cells, rats and swine. Ipamorelin showed GH-releasing activity through a GHRP-like receptor. In swine, its ACTH and cortisol responses were not significantly different from those after GHRH stimulation, even at high tested exposures. This is an encouraging preclinical selectivity finding, not a matched human comparison proving years of low-risk treatment. Original animal experiments
The same swine experiment did not find prolactin changes with any of the tested secretagogues. It therefore cannot establish that ipamorelin uniquely prevents prolactin effects in people. Selectivity, tolerability and a useful clinical outcome require separate evidence.
GHRP-2: Human Hormone and Appetite Research
A study in ten healthy men gave an intravenous GHRP-2 test with and without fasting. GH, ACTH and prolactin responses increased, with higher responses during fasting; vasopressin was not stimulated. That finding does not support a blanket cortisol-suppression claim or show that fasting improves muscle growth. Original human hormone study
In a separate crossover experiment, seven lean healthy men received a subcutaneous GHRP-2 infusion or saline before a buffet-style meal. Food intake was 35.9% higher with GHRP-2, and every participant ate more. This is direct acute appetite evidence, not a chronic bulking, weight-loss or head-to-head ipamorelin trial. Original food-intake study
GH Measurements Are Not Muscle-Gain Units
The human ipamorelin PK/PD study used five 15-minute infusion exposures, with eight healthy men at each level. The peptide terminal half-life was approximately two hours and the GH peak occurred at 0.67 hours, with substantial variation in the modeled hormone response. Those measurements do not supply a subcutaneous injection calendar. Original human PK/PD study
The reported modeled maximum GH production rate was 694 mIU/L/h. This is not a blood concentration, a universal “IU per pulse” result or the IU dose of a growth-hormone injection. A useful comparison must match route, dose, population, sampling and assay before comparing hormone peaks. Neither the magnitude of a GH response nor a short-term hormone marker establishes muscle gain or injury recovery.
Clinical Findings and Their Limits
A randomized postoperative ipamorelin trial enrolled 117 bowel-resection patients; 114 entered the safety and modified intention-to-treat analyses. Median time to a tolerated meal was 25.3 versus 32.6 hours with placebo, but the difference was not statistically significant (P=0.15). Key and secondary efficacy analyses were neutral. The authors described up to seven days of intravenous treatment as well tolerated; this is not long-term subcutaneous safety or a bodybuilding result. Original postoperative trial
The official registry links the same publication and identifies 117 participants. These are two records of one trial, not independent replications. NCT00672074
Both compounds have biological activity worth studying. The evidence compared here does not establish predictable muscle gain, longer life, accelerated rehabilitation or an age-based choice between “lean gains” and “rapid size.” Reports from users should remain identified as experience, with concurrent training, nutrition and other treatments considered.
Study Exposure Is Not a General Administration Plan
The human studies used different intravenous tests and infusions, or a short subcutaneous infusion. They do not validate a universal repeated-injection dose, fasted or pre-workout timing rule, months-long cycle or weekend reset. A peptide half-life does not by itself determine an effective and safe clinical regimen. Ipamorelin design; GHRP-2 design
The cited studies also do not establish that combining ipamorelin and GHRP-2 improves body composition or offsets prolactin, cortisol or other adverse effects. More hormone stimulation is not evidence of better long-term outcomes or formulation compatibility.
Safety Requires Product, Route and Population Context
FDA identifies aggregation, impurity and immunogenicity concerns for both substances. Its GHRP-2 entry describes reports including increased insulin requirements, deaths in critically ill participants, infection and pancreatitis, while explicitly noting that causality has not been established. Its ipamorelin entry describes serious events, including death, in intravenous gastric-motility research and information gaps for other injectable routes. Those records deserve attention without turning associations into proven causal rates for every user. Read the separate FDA entries
The studies here do not establish a prolactin threshold that automatically requires cabergoline, or a dopamine-agonist dose to add to a peptide cycle. A suspected adverse effect needs assessment of symptoms, the actual product, other medicines and relevant tests. Adding another hormone-active drug should not be presented as a routine way to make an unvalidated regimen safe.
Compounded preparations are not FDA-approved, although compounding can serve legitimate medical needs under applicable conditions. A research label, a prescription or online availability does not establish the quality, compliance or clinical suitability of every product. FDA compounding context; peptide safety evidence.
Choose the Clinical Question Before a Product
No general muscle-growth or long-term safety winner is established by these studies. Ipamorelin’s animal selectivity and human PK findings answer different questions from GHRP-2’s acute food-intake and hormone-response studies. A prescriber should first establish the diagnosis and intended outcome rather than assign a peptide from age, training intensity or willingness to manage side effects.
For cost comparisons, obtain a dated quote for the exact preparation, amount supplied, consultation, testing and follow-up. A research-vial price alone cannot establish the cost of an equivalent clinical program. Continue with the ipamorelin and GHRP-2 profiles for source and route distinctions.
Medical Context
This comparison explains study findings and product context. It does not define an individualized treatment, injection or side-effect-management plan. The relevant clinical decision depends on the diagnosis, exact preparation, evidence and appropriate follow-up.
Frequently Asked Questions
The studies compared here do not establish a matched muscle-growth winner. Ipamorelin human research includes PK/PD and postoperative gastrointestinal outcomes; GHRP-2 studies include acute hormone and food-intake outcomes. A GH production rate, serum concentration and injected IU dose are different quantities and cannot be converted into a guaranteed muscle-gain ranking.
The cited evidence does not validate a routine combined regimen or show that ipamorelin offsets GHRP-2 adverse effects. A stronger hormone stimulus does not demonstrate better body composition, safety or compatibility in the same preparation. These studies do not supply a personal stack or dosing calendar.
An acute study in seven lean men found increased test-meal intake during subcutaneous GHRP-2 infusion. That supports an appetite effect in that setting, but is not a matched long-term comparison with ipamorelin. Animal selectivity does not establish that ipamorelin is free of appetite, fluid or hormone effects in people.
A reliable muscle-growth timeline is not established by these sources. Hormone-response, PK/PD and gastrointestinal studies cannot predict visible changes after a fixed number of weeks. Training, nutrition and other treatments also make personal reports difficult to interpret causally.
A long-term safety advantage has not been established. Ipamorelin has favorable animal selectivity and limited short-term human observations, while FDA identifies compound- and route-specific concerns and information gaps. Neither those findings nor acute GHRP-2 studies establish that extended self-treatment is safe.
Use a current, dated quote for the actual preparation and equivalent supply and services. Consultation, laboratory assessment, supplies and follow-up may differ. A vial price or injection-frequency comparison alone does not establish which clinical program costs less or offers better value.